Sentinel Lymph Node Biopsy (SLNB) participates to reducing morbidity & improving quality of life 

Breast cancer is the most common cancer in women

Sentinel Lymph Node Biopsy (SLNB) participates to reducing morbidity & improving quality of life 

SLNB in patients with operable breast cancer helps showing whether the cancer has spread to the lymph nodes.   

Statistics 772X579

Statistics

Breast cancer still an important cause of death

• Breast cancer is the second most common cancer
in the world 1
• Most frequent cancer in women: 2.089 million new cases diagnosed in 2018 (11.6% of all cancers) 1
• 5th cause of death from cancer overall (626,679 deaths in 2018) 1

SLN Identification 772X579

Sentinel Lymph Node Identification (SLNI)

Marking sentinel nodes before biopsy in patients with operable breast cancer can be done with the blue dye Patent Blue V. 

• Injection into the immediate area surrounding the tumor or into the tumor bed periaeolar
• Subcutaneous but not intradermal injection
• Systematically breast massage

Patent Blue V: See & make the right choice

Patent Blue V is indicated for marking sentinel nodes before biopsy in patients with operable breast cancer

Learn more

The site is not country specific and may vary from the approved product information in the country where you are located. Please refer to the local prescribing information and Summary of Product Characteristics (SmPC). Some products mentioned in this website may not be registered, nor commercially available in all countries. Please contact your local Guerbet representative.

Bibliography

1. GLOBOCAN, Cancer Fact Sheets: Breast cancer, 2018, https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf